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Calcium phosphate nanocoatings and 
nanocomposites, part 2: thin films for slow 
drug delivery and osteomyelitis 
During the last two decades although many calcium phosphate based nanomaterials 
have been proposed for both drug delivery, and bone regeneration, their coating 
applications have been somehow slow due to the problems related to their complicated 
synthesis methods. ln order to control the efficiency of local drug delivery of a 
biomaterial the critical pore sizes as well as good control of the chemical composition is 
pertinent. A variety of calcium phosphate based nanocoated composite drug delivery 
systems are currently being investigated. This review aims to give an update into the 
advancements of calcium phosphate nanocoatings and thin film nanolaminates. ln 
particular recent research on PLA/hydroxyapatite composite thin films and coatings 
into the slow drug delivery for the possible treatment of osteomyelitis is covered. 
Keywords: antibiotics • biofilm • drug delivery • hydroxyapatite • nanocoatings 
• nanocomposites • nanolaminates • osteomyelitis • thin films 
During the last hundred years due to its simi­
lari
ty 
to hard tissue, the material of choice 
for the enhancement of bioactivity has been 
calcium phosphates (1-6). A number of bio­
degradable nanocoated biomaterials based 
on calcium phosphates are currently being 
examined for applications for slow drug 
delivery and dispersion of pharmaceuticals 
and minerais to the targeted area. In these 
new devices, which comprises a polymeric 
or ceramic matrix and porous inorganic par­
ticulate matter, factors such as the chemical 
composition as well as the critical pore size 
are the main factors that influence the disso­
lution rates. Additive particulate sizes which 
can be incorporated to these films can be 
from a few nanometers up to microns depen­
dent on the required thickness and the fonc­
tion of the films. They are usually designed 
to contain nano and meso pores for drug 
loading. 
Classical approach of the systemic drug 
delivery has in the past generated a num-
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ber of problems that can possibly be solved 
by local or targeted delivery. These include 
influence of the dissolving drugs to the whole 
body rather than pin point loca.l delivery. 
Moreover, aside from reduction of toxicity to 
healthy cells within the whole environment, 
targeting these drugs directly to required 
locations have the possibility of improving 
drug efficacy and efficiency, resulting in a 
significant cost savings for the health care 
system. 
During the last decade a number of 
research groups have been describing the pro­
duction of nove! nanocoatings and thin film 
nanolaminates with hydroxyapatite (HAp) 
and other calcium phosphates for clinical 
applications. The nano to micro particles 
of oxide or mixed ceramics, and calcium 
phosphates are the inorganic components 
and natural or synthetic polymers such as 
collagen, chitosan and biodegradable poly­
mers such as polylactic acid (PLA) are the 
matrix materials in these new composites. 
Besim Ben-Nissan*•1, Innocent 
Macha1 , Sophie Cazalbou2 
& Andy H Choi1 
1 Faculty of Science. un iversity of 
Technology Sydney. 15 Broadway. Ultimo 
NSW 2007. Australia 
'Université de Toulouse. C IRI MAT. 
UMR 5085 UPS-INPT-CNRS. faculté de 
pharmacie. Toulouse. France 
•Author for correspondence: 
b.ben-nissan@uts.edu .au 
These nanocomposites can be synthesized by mixing 
the inorganic particles physically through heat or by 
solvent introduction into an already existing polymeric 
matrix material. Evaporation of the solvent aids the 
formation of the nanocomposite or the thin films.
The development of tissue engineering in the past 
has been related directly to the types of scaffolding 
materials used. At present, a number of synthetic bone 
graft biomaterials such as calcium phosphates are avail-
able as options to autogenous bone for augmentation, 
repair or substitution [3]. New advancements associated 
with calcium phosphate scaffolds and their improve-
ments in microstructure and surface properties have 
created new opportunities for bone regenerative tech-
nologies. These recent developments also make the cal-
cium phosphate scaffolds to be thought of as being at 
least biologically constructive instead of as only osteo-
conductive scaffolds specifically with the addition of 
biologic materials such as bone morphogenic proteins 
and stem cells [7–9].
Evidence has shown that porous calcium phosphate 
has a direct influence on the proliferation and differ-
entiation of human mesenchymal stem cells (MSCs). 
Tissue engineering along with new bioactive molecules 
enhanced the possible applications of calcium phos-
phate as scaffolds able to guide the behavior of these 
cells and the efficiency of bone regeneration as well as 
being carriers of these cells [7,9].
In this review, we aim to introduce the recent devel-
opments of nanocoatings and thin films and compos-
ites containing calcium phosphate-based nanoparticles 
currently being investigated for the delivery of phar-
maceutical substances and their use in medicine and 
specifically for the treatment of osteomyelitis.
Surface modifications & liposomes for drug 
delivery applications
In bioceramics, the critical pore size and intercon-
nectivity can be altered in order to control the ease of 
delivery and dispersion of a material to the targeted 
area. Targeting usually achieved with appropriate 
functionalizing of the surfaces. The pores may range 
from a few nanometers to micron sizes dependent on 
the pharmaceuticals used or areas intended to be deliv-
ered such as long bones. Delivery systems based on 
calcium phosphate which is similar at least chemically 
to the hard tissues, have the potential to increase drug 
efficacy while at the same time minimizing toxicity to 
nondiseased cells. Nano drug-delivery systems, embed-
ded within a matrix or not, also have the exceptional 
attribute of being capable of delivering and control-
ling dissolution with high precision due to their high 
surface areas. It is not surprising that the number of 
research papers covering drug, gene and mineral deliv-
ery of nanoparticles, nanocoatings and composites 
published during the last decade is very high [9–32].
The appropriate dissolution rates and their con-
trol within the human body is the main concern for 
drug carriers containing nanoparticles and nano thin 
films [33]. The use of calcium phosphate as a delivery 
system also broadens its effectiveness as a result of their 
capacity to locally deliver minerals as well as calcium 
and phosphate, other active ions and biogenic materi-
als such as bone morphogenetic proteins (BMPs) and 
MSCs if required to be used in the successful treat-
ment of bone diseases. In addition the surface modifi-
cation approach it can also be used to achieve enhance-
ments of stability and long range solubility control of 
nanocoatings and thin films in aqueous media, as well 
introduction of new material properties and functions. 
In principle through the use of a wide range of bio-
logical, chemical and/or physical surface modifications 
methods, the surfaces of nanostructured materials 
such as nanocoatings can be altered and functional-
ized to assist us in slow drug delivery. In the quest for 
the surface modifications of nanostructured materials, 
approaches such as macro micro and nanocoating have 
emerged as the leading strategies resulting in better 
functionalization of the surfaces of materials and for 
better osseointegration in the long term.
The biological modification of surfaces of nanocoat-
ings is at times essential for the functionality of the 
devices. Biospecific molecules can be incorporated into 
the nanocoatings or thin films by using physical or 
chemical methods, thus presenting biospecific sites for 
the further immobilization of ligands specific to these 
molecules. The immobilizations of specific ligands 
such as antibody–antigen and receptor–ligand can be 
carried out using biologically specific reactions [34]. 
Current research work in these areas is very promising.
It is well known that different biomedical applica-
tions require different functions and properties of 
materials. As a result, techniques available to mod-
ify nanostructured materials or thin films can vary 
in order to meet the demands of various biomedical 
systems. In spite of the advantages offered by nano-
coatings and nanoparticle containing composite thin 
films, such as their small surface pore sizes and load-
ing efficiency, a number of issues such as control of 
the appropriate drug release rates, restricted their use 
clinical applications.
The targeting ability and efficacy of any drug deliv-
ery system are sometimes hindered by the rapid dis-
solution of the carrier system within the human body. 
A good example is their side effects in chemotherapy 
drug delivery for the cancer patients. The long circula-
tion time within the blood is the primary concern for 
drug carriers of both local and systemic delivery. For 
this reason, a number of investigations have been car-
ried out to examine ways in which ‘long-circulating-
time’ carriers can be designed and engineered. Among 
these, the surface modification of thin films and 
nanocoatings with a variety of polymeric macromol-
ecules or nonionic surfactant has been demonstrated 
to be the most effective for maintaining the presence 
of drug delivery particles in the blood for prolonged 
periods [35].
The use of surface modification is used in gene ther-
apy in an effort to obtain controlled delivery of small 
interfering RNA and plasmid DNA (pDNA) particu-
larly in an acidic pH environment [25–28]. The use of 
cationic liposomes as transfection vectors has become 
an ideal choice and most widely employed in the trans-
fer of pDNA due to their weak immunogenicity and 
low toxicity [24]. A study by Zhou et al. [25] has suggested 
that coating calcium phosphate with liposomes could 
provide consistently efficient and satisfactory delivery 
of pDNA. Using mammalian cell culture, their find-
ings showed the application of a lipid coating resulted 
in a tenfold increase in the transfection of pDNA 
compared with uncoated calcium phosphate [25].
Considered as one of the most clinically recognized 
thin film nanoscale systems, liposomes consist of a 
single layer or multiple concentric lipid bilayers that 
encapsulate an aqueous compartment are currently uti-
lized in the delivery of antifungal drugs, vaccines and 
genes [25,36–41]. The exceptional clinical profile of lipo-
some coatings in comparison to other delivery systems 
is based on their reduced toxicity, biodegradability and 
capacity for size, and surface manipulations [42]. An 
improvement in the biocompatibility of liposomes as 
well as an increase in nanoparticle hydrophilicity and 
stability in plasma can be achieved through the encap-
sulation of nanomaterials such as calcium phosphate 
within liposomes (Figure 1). In Lewis work multilay-
ered liposomes were produced with the incorporation 
of nano-HAp and other minerals such as strontium, 
magnesium and zinc [42]. Figure 1 shows a transmission 
electron microscopy (TEM) image of multilayered 
liposomes containing nano-HAp particles produced 
in a calcifying buffer. The figure was obtained in FEI 
Morgagni 268D transmission electron microscope 
(Eindhoven, the Netherlands) at 80 kV [42]. The work 
showed an excellent encapsulation that can help to 
control drug delivery rates in medical applications such 
as chemotherapy drug delivery for oncology patients. 
This observed ease of coating and release delay ability 
is one of the strong reasons, calcium phosphate based 
nanoparticle containing thin films and liposome coat-
ings are ideal candidates for drug delivery and bone 
regeneration systems [42–45]. In addition, combinatory 
therapy–modalities can be accomplished by utilizing 
the ability of liposome coatings to carry hydrophobic 
and hydrophilic moieties as well as their capacity to 
incorporate therapeutic and diagnostic agents into a 
single liposome-delivery system [42].
Huang et al. [39] have suggested that the nucleation 
process for new bone formation could be improved by 
the presence of negatively charged liposome coatings. 
In their experiments carried out in miniature swine, 
artificial bony defects on one side where implanted with 
liposome-coated tri calcium phosphate while defects 
on the other side served as controls. They reported that 
at three weeks postimplantation, dense connective tis-
sues surrounded the implant material and new bone 
formation was visible after 6 weeks.
Using a different strategy, Wang et al. explored the 
possibility of producing collagen-calcium phosphate 
scaffolds with the incorporation of liposome thin films 
for the controlled release of bioactive molecules in 
bone regeneration and repair [40]. They suggested that 
bisphosphonate (BP) functionalized liposome encap-
sulation could be isolated within mineral-containing 
scaffolds can be better drug delivery system that local-
ize their drug cargo to the directed area. The liposome 
encapsulation used consisted of cholesterol, distearo-
ylphosphodioline, distearoylphosphoethanolamine-
poly(ethylene glycol). Based on their observations, 
the encapsulation of BP within liposomes displayed a 
strong affinity to the scaffolds and the drugs entrapped 
within the BP-liposomes showed a slower release rate 
from the scaffolds as compared with drugs that were 
un-encapsulated or encapsulated in polyethylene gly-
col-liposomes. In a similar study by Chou et al. it was 
shown that this liposome coating thin films reduced 
the drug release rates in both BP and antibiotic 
additions [22,46].
A study by Xu et al. [36] explored the possibility of 
synthesizing a multifunctional thin film drug car-
rier with sustained drug release capability provided 
by the inner core liposome and osteoconductivity for 
bone cells supported by the HAp outer layer. The lipo-
somes were produced from 1,2-dimyristoyl-sn-glycero-
3-phosphate and 1,2-dimyristoyl-sn-glycero-3-phos-
phocholine, which is then loaded with the lipophilic
drug indomethacin. The release profile of indometh-
acin was measured at two different pH levels (4 and
7.4). As expected by coating the liposome with HAp,
they reported a reduction in release rate of indometha-
cin in comparison to uncoated liposomes. They also
reported that without these coatings, the rate of drug
release occurred more rapidly at pH 7.4 rather than at
pH 4.
It has been reported that the management of pos-
sible postoperative infections from bone grafts and 
prostheses as well as the treatment of bone diseases 
Figure 1. Transmission electron microscopy image of 
multilamellar lipsomes containing nano hydroxyapatite 
particles and minerais in a calcifying buffer (scale 
500 nm). 
Reproduced with permission from [42]. 
such as bone metastases will benefit gready if there 
is a delivery system which has a high affinity toward 
bone tissues thereby maximizing its therapeutic effect 
on bone-related diseases (36,39]. Using this approach, 
Anada et al. (37] attempted to develop a calcium phos­
phate-binding liposome coating for a bone targeting 
drug delivery system by synthesizing an amphipathic 
molecule bearing a BP head group to recognize and 
bind to HAp. Liposomes loaded with the drug doxoru­
bicin adsorbed onto the surfaces ofHAp were observed 
to significandy reduce the number of viable human 
osteosarcoma MG63 cells. Based on these observa­
tions, they suggested that the system can be excellent 
coated carriers for anticancer drugs as they specifically 
target bone tissue (36]. 
Infection & osteomyelitis 
lt is widely accepted in the medical community that 
wound contamination as well as postoperative infec­
tions following implantation or during surgical inter­
vention in orthopedics and maxillofacial surgery can 
result in serious clinical problems and could jeopardize 
the osseointegration process. For these reasons, antibi­
otics either administrated orally or intravenously are 
often provided as prophylactics. 
By far the most frequent complications related to the 
use of implantable medical devices such as orthopedic 
or dental prostheses and endotracheal tubes are bacte­
rial infections. Pseudonomas aeruginosa is regarded as 
an opportunistic pathogen causing indwelling device­
related infections especially catheters. P. aeruginosa 
infection is leading cause of morbidity and mortality 
in cystic fibrosis patients. On the other hand Staphy­
lococcus aureus infection causes serious infectious 
complications such as severe sepsis, septic-thrombosis 
and/or severe deep-seated infections (endocarditis, 
osteomyelitis and other metastatic infections). One of 
the basic hospital and surgical intervention acquired 
biofilm infections are those associated with S. aureus 
and Staphylococcus epidermidis mains, including meth­
icillin-resistant S. aureus (MRSA). A thorough and 
comprehensive understanding of the molecular bases 
of biofilm formation and their adhesion may help us to 
fight biofilm infections. 
Osteoarticular infection is frequendy caused by 
coagulase-negative Staphylococci as main aetiologic 
agents in lace infections as well as Streptococci, Entero­
cocci and anaerobes. The number of infections is esti­
mated to be around 0.5- 2.0% of cases and it increases 
continuously due to the rise in the need for implants. 
The European Center for Disease Prevention and 
Controll (ECDPAC) reported that approximately 
4,100,000 patients are estimated to acquire infections 
in the European Union every year (47]. The number 
of deaths occurring as a direct consequence of these 
infections is estimated to be at least 37,000 patients 
and these infections are thought to contribute to an 
additional 110,000 deaths each year. ln the USA, it 
was estimated that approximately 1,700,000 patients 
acquired infections for the year 2002. lt has been esti­
mated that 5% of patients undergoing clean surgical 
procedures and up to 20% of patients having intra­
abdominal surgical procedures develop a surgical site 
infection. Such infections result in 3.7 million excess 
hospital days and more than US$1.6-3 billion in 
excess hospital costs per year. 
ln order to mitigate this problem different strate­
gies have been proposed on either preventing and/or 
controlling bacterial infections. Modification or devel­
opment of thin film or nanocoated multilayer devices 
with surface properties that have an effect against 
microbial adhesion or viability seems to be a promis­
ing approach for the prevention of device-related infec­
tions. Another strategy is to modify the surface of 
medical devices biologically, chemically or physically 
to render the surface free of microbial adhesion. Mul­
tifunctional thin films or nanocoatings can facilitate 
this new approach. 
ln clinical applications an ideal implant coatings 
must provide surgeons with several benefits such as 
providing primarily anchorage with appropriate bioac­
tivity involving osteoconduction and if possible, osteo­
induction. The nanocoating or thin films used should 
also provide antimicrobial property to prevent implants 
from developing acute or postoperative infections. 
As stated earlier the development of bone infec­
tion is based on the formation of a bacterial biofilm 
where the bacteria differentiate from planktonic into 
sessile forms that protect some bacterial cells that can 
be released from the biofilm after antibiotic treatment 
has ceased.
Bacteria adhesion is a complex phenomenon 
affected by many factors, including properties of sur-
face materials, some characteristics of bacteria itself 
and the environment where the adhesion takes, such 
as the presence of serum protein or bactericidal sub-
stances [48]. Some of the proposed theory and model 
of adhesion seem to be limited because they consider 
physical interaction between the surface and bacteria 
and neglecting biological aspects of adhesion in which 
specific bacterial structure responsible for adhesive 
activities called adhesins that control cell to cell or cell 
to abiotic surface adhesion. Bacteria may have differ-
ent adhesives for different surfaces (different acceptor). 
The ionic strength and pH of the medium in which 
the adhesion takes place influence the charge of the cell 
wall and of the substrate (in terms of surface chemistry, 
charge and hydrophobicity) and therefore affects their 
interaction.
The antibiotic dosage required to act on bacteria in 
biofilm conditions can be many folds higher in con-
centration of the drug required for treatment of plank-
tonic cells. Consequently, it is difficult to completely 
eradicate active infection by means of ‘systemic anti-
biotics’ which in doses active in biofilm can be toxic 
for a patient.
In orthopedics, osteomyelitis mainly occurs in tis-
sues within the infected area, and consequently tar-
geted delivery of antimicrobial agent locally is a more 
appropriate form of treatment. One of the most effec-
tive ways of achieving targeted delivery of antibiotics is 
to use a carrier device that can be placed into the body 
at a specific site such as coating on an implant, which 
will release slowly the correct antibiotic dosage. The 
major challenge associated with the use of antibiotic is 
ensuring retention of antibiotic release and activity for 
a prolonged period of time post operation [49].
Treatment of osteomyelitis can be with immobili-
zation and antibiotic therapy with a number of drugs 
including flucloxacillin, gentamicin, tobermycin or 
vancomycin, and fusidic acid. Surgical drainage and 
removal of damaged bone, as its presence prevents 
healing, sequestrum may be possible but recurrence is 
common. Currently, commercial products in the form 
of pellets composed of acrylic polymers or ceramics 
such as calcium sulfate or bioactive glass are available 
as slow drug delivery devices. However, due to the 
problems related to their dissolution rates, shape, sizes 
and chemical composition, they are either nonresorb-
able that requires second surgery to remove or quickly 
resorbed by the body’s natural physiological process, 
thus limiting their effectiveness. In addition, past 
investigations have shown that some antibiotics have 
been reported to be ototoxic and nephrotoxic at high 
dosage. For most controlled release systems, the loaded 
dosages are usually high, and therefore the systemic 
exposure of antibiotic in blood and urine is the major 
safety concern.
The concept of pathophysiology of osteomyelitis 
which has been widely accepted is the infected bone 
becomes devascularized and the resulting sequestered 
portions of necrotic cortical bone harbor bacteria. This 
sequestered, necrotic, infected bone is responsible for 
the chronicity of osteomyelitis. Pus and granulation tis-
sue then surrounds the infected fragments and through 
increased intraosseous pressure, bacterial toxins and 
enzymes, further contribute to devascularization of 
the surrounding bone. The granulation tissue that 
surrounds the infected area as the infection becomes 
chronic is replaced by relatively avascular fibrous tis-
sue, and stimulation to form new reactive bone referred 
to as involucrum takes place within the surrounding 
tissues and in the periosteum permeative mesenchy-
mal cells that wraps around the sequestered, necrotic, 
infected bone. Antibiotics and antibodies must cross 
this involucrum and relatively avascular fibrous tis-
sue to reach the microorganisms once the fibrous and 
bony encapsulation takes place. Consequently, the very 
effective effort by the body to quarantine the host from 
the infection also isolates the microorganism from the 
defenses of the host. The infection becomes chronic 
and cannot be eradicated when this pathological stand-
off occurs. This condition is the basis for intervention 
surgery and the excision of necrotic sequestra. Antibi-
otic therapy completes the treatment of chronic osteo-
myelitis by eradicating the microorganisms once they 
are no longer isolated [50].
The quest for a more effective means of delivering 
antibiotics without the complications related to long-
term intravenous access and the toxicity of systemic 
antibiotics has been ongoing. Hence, the most accurate 
method of assessing diseases is provided by models that 
utilize eradication of infection as a criterion for suc-
cess, the histological findings of new bone formation, 
inflammation, sequestration and intraosseous bacteria, 
combined with cultures.
In the past, ceramics as well as other materials 
incorporated to the thin films and bulk composites 
have been suggested as potential candidates to be 
used as biodegradable drug delivery systems. How-
ever, manipulating these materials into an appropri-
ate shape with adequate microporosity in order to be 
fitted into bone defects of different size and form was 
found to be difficult. Recently, it has been demon-
strated that marine shells, foraminifera and corals 
incorporated into thin films and nanocoatings with 
specific microspherical carriers offer desired functions 
for the delivery ofBP (paminodrate) and an antibiotic 
(gentamicin) [51-55). This has been possible by virtue 
of its nano and mesoporous structure and architec­
ture of the foraminifera shells (Figure 2A) which are 
difficult if not impossible to produce with our cur­
rent manufacturing methods [44,45). Foraminifera 
and coral in addition to their unique interconnected 
porous structure are made of calcium carbonates that 
can be easily converted to bone such like phosphate 
structures [44,45). 
B one repai r drug delivery systems 
& osteomyelitis 
In early 1900s, a calcium phosphate compound (tri­
calcium phosphate) was first successfully used in bone 
repaie followed by the first clinical study [!). It took 
more than six decades until porous calcium phosphate 
scaffolds were proposed for the treatment of bony 
defects [2). The reason behind the research and devel­
opment of calcium phosphate based biomaterials for 
bone repaie, augmentation and substitution was due to 
the similarity in composition between biological and 
synthetic apatites [55). 
For bone repaie and slow drug delivery systems, 
the most appropriate materials are the calcium phos­
phate based bone substitutes [3). They offer easy pro­
duction, drug carrying capability and supply both 
calcium and phosphates during dissolution. They can 
be easily incorporated within thin films and nanocoat­
ings [55.56). There have been a large number of stud­
ies carried out on both experimental and commercial 
calcium phosphate based drug carriers during the last 
decade [10-34). Due to their wide areas of applicabiliry, 
the delivery of antibiotics has become a major focus in 
the prevention and treatment against infection during 
or postoperative surgical interventions. 
Biodegradable composite thin films 
Biodegradable polymer thin films loaded with gen­
tamicin have been synthesized to act as a 'composite 
coatings' for metallic implants and fracture fixation 
devices in an attempt to prevent implant-associated 
infections [48.57-59). Due to their tendency to uptake 
and release pharmaceuticals and minerais as well as the 
capability to degrade over time, the use of biodegrad­
able polymer thin films is advantageous. In addition, 
by controlling the pore sizes and interconnectiviry 
of these particles, the rates of drug release could be 
tailored to suit the treatment. 
In our experimental work [53-59], hydrothermally 
converted coralline HAp particles containing nano 
and mesopores were loaded with medically active sub­
stances, which cover both the surfaces and intercon­
nected pores of the particles that ranged from a few 
hundred nanometers to micron sizes (Figure 3). 
The influence of HAp particles within PLA matrix 
on the relea:se of gentamicin as well as its release kinet­
ics have been previously examined [59). lt was discov­
ered that the release kinetics of gentamicin appeared to 
obey "Power law Korsmeyer Peppas' mode! with mostly 
diffusional process through a number of different drug 
transport mechanisms. Statistical analysis revealed a 
very significant difference on the release of gentamicin 
between gentamicin-containing PLA (PLAGM) and 
gentamicin-containing HAp microspheres within PLA 
matrix (PLAHApGM). 
These thin film composite coatings, such as PLA­
HApGM displays slower release rates than PLA matrix 
Figure 2. (A) Foraminifera hydroxyapatite microsphere. (B) Enlarged degraded surface of Foraminifera 
hydroxyapatite structure within simulated physiological environment. 
Figure 3. (A) Hydrothermal converted coralline hydroxyapatite surface. (B) Gentamicin-coated coralline
hydroxyapatite surface. 
alone. As stated earlier HAp and other calcium phos­
phates are also the source of Ca2• for the regeneration 
and repaie of diseased bone tissue. lt was also reported 
that the release profiles, exhibited an early burst stage 
and then a steady state release rate with significant 
antimicrobial activity against S. aureus (SHIO0O) even 
at high concentration of bacteria. The devices also 
indicated significant ability to control the growth of 
bacterial even after 4 weeks of drug release. It was sug­
gested that clinical release profiles can be easily tuned 
from drug-HAp physicochemical interactions and deg­
radation kinetics of polymer matrix. lt was concluded 
that the developed systems could be applied to prevent 
microbial adhesion to medical implant surfaces and to 
treat infections mainly caused by S. aureus in surgery. 
lt was reported that the degradation of the poly­
meric network towards the end of the initial release 
will 'favor' the dissolution of any drug residue. Accord­
ingly, this phenomenon (diffusion and degradation) 
should take place at the conclusion of surface drug 
release (when dissolution of drug have created second­
ary porosity inside the polymeric network and resul­
tant 'fragility' of it) and/or dependent on factors such 
has the surface area, dissolution rate and the molecular 
weight of the PLA film used. 
For the coral converted to hydroxyapatite material 
(coralline HAp) structure contains meso- and nano­
pores and during the initial drug loading period gen­
tamicin penetrates the pores of the 'HAp-coral' and 
coats its surfaces and its porous network. The gentami­
cin contained in these porosities will be released gradu­
ally. Hence, the process of polymeric matrix thin film 
composites containing drug carrying particulate mat­
ter can be thought to proceed in three stages that can 
be named as 'progressive dissolution process'. 
In the first stage (stage 1), the initial release (burst) of 
gentamicin can be regarded as the direct dissolution of 
surface bound drugs in water or the physiologie environ­
ment due to the exposed outer surface area and concen­
tration gradient. lt was shown in that the initial burst 
took approximately 1 week for gentamicin. At this stage 
it can be assumed that the release is purely governed by 
diffusion of drugs from polymeric matrix surface (60,61]. 
In the second stage the dissolution is driven by 
the internai diffusion of drugs impregnated within 
the matrix possibly in the porous part of the matrix 
generated during preparation. For gentamicin release 
from PLAHApGM samples, this stage is preceded by 
'lag phase' which occurs between 1 and 2 h of release. 
The presence of HAp loaded with gentamicin could 
in many ways hinder (or slow down) the release of 
gentamicin through these micropores. This stage is 
relatively much slower compared with the previous 
one due to the drug transporting through mainly from 
the surface areas and large pores of the particles. This 
stage proceeds with release from narrow pores of the 
nano and mesopores of the particles to the matrix and 
then to the environment. There is no degradation of 
particles at this stage but dissolution of the drugs only. 
The third stage involves slow degradation of the 
polymeric matrix combined with dissolution and 
deterioration of the particles (Figures 4 & 2B) and slow 
release of the added drugs or the minerais into the 
environment. This is terminal release phase or stage 
for loaded devices. At this stage, there is pore growth 
due to both mass loss by polymer degradation and 
pore coalescence (micropores coalescing (or joining) 
to form larger pores). In recent dissolution studies of 
BPs, for the device containing HAp (PLAHApBP), the 
slower dissolution rates observed were reported to be 
due to the strong bonding of BP to apatite (HAp) as 
well as encapsulation within the particles. It was ear­
lier reported that for BP containing calcium phosphate 
particles have strong affinity to the nanocrystalline 
apatites with adsorption phenomena that occurs at the 
surface of apatite crystals (62].
Antibacterial efficacy & biofilm formation 
Published work states that poor diffusion and penetra­
tion of antibiotic through the biofilm, contribute to 
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Figure 4. Gentamicin drug delivery device produced from polylactic acid-coralline hydroxyapatite thin film 
composite. (A) The scanning electron microscopy image of the coralline HAp surface used for drug delivery (only 
the struts are used as drug delivery vehicles shown in a circled area), and (B) drug release profile of only the 
gentamicin within PLA (PLAGM) and HAp coralline particles loaded with gentamicin embedded within a PLA 
matrix (PLHApGM) showing lower amounts of drugs released as well as a longer release rate up to 8 weeks. 
GM: Gentamicin; HAp: Hydroxyapatite; PLA: Polylactic acid. 
the persistence of biofilm infections especially those 
associated with implanted devices [63-66]. A number 
of reasons on the microbial resistance to antimicrobial 
agents have been postulated. An increase in the deple­
tion of oxygen and nutrients resulting into slow growth 
of bacteria, adaptive stress responses and formation of 
persister cells are hypothesized to constitute a multi­
layered defense. In recent research efforts the focus is 
directed toward disabling biofilm resistance, which 
may enhance the ability of existing antibiotics to treat 
infections involving biofilms [67). lt has been reported 
that in most cases, biofilm can be prevented aggres­
sively by antibiotic in their early stages and can also be 
treated by chronic suppressive therapy. Mah et al. [68) 
suggested that the use of traditional antibiotics com­
bined with drug that interferes with biofilm-specific 
resistance would be the right approach to render 
biofilms more susceptible to treatment. 
A recent study by our group has suggested that effec­
tive drug delivery devices with adequate slow release 
rates can be produced using converted coralline HAp 
particles loaded with medically active drugs and sub­
stances embedded within a PLA thin film matrix [48,58-
59). To investigate the antibiotic delivery efficiency of 
the composite thin films produced and observe the 
biofilm formation, we carried out a number of tests. 
In this current work, we prepared PLA films and 
film composites based on the previously published 
work and loaded with gentamicin. Schematic repre­
sentation of the process is given in Figure 5. The films 
were eut inro circular shape and glued on the sterilized 
cylindrical coupons. They were sterilized using UV for 
40 min. Trytpic Soy Broth (TSB) for S. aureus and 
Mueller Hinton II BR cation adjusted media (MHB) 
for P. aerugonas were prepared by thoroughly dissolv­
ing 30 g of TSB powder (BactoTM TSB (BD) and 22 
g of MHB powder in I I of polished 18 MQ (MilliQ, 
Millipore, Victoria, Australia) water, respectively. The 
solutions were autoclaved to sterilize (121°C, liquid 
cycle) and stored at room temperature. 
Staphylococcus aureus (ATCC 25923) and 
P. aeruginosa (ATCC 15692) were used for this study
and were cultured in a shaking incubator, 250 rpm at
37°C under anaerobic and aerobic conditions, respec­
tively. For static biofilm formation, cells were grown in
broth medium overnight, and diluted I: 100 into TSB 
and MHB media, respectively. These cell suspensions
were inoculated into a 12-well plate containing tripli­
cate of samples glued on coupons. The plate was sealed
with sterile breathable film (Aeraseal; Excel Scientific,
CA, USA) and statically grown at 37°C, 5% C02 for
24 h. Biofilm samples were washed with PBS, stained
using SYT09 Green fluorescent Nucleic Acid Stain
(Life Technologies Corp, CA, USA) and fixed with 4%
paraformaldehyde.
The morphological changes of the biofilms were 
analyzed using confocal laser scanning microscopy 
(CLSM; Nikon AI, Tokyo, Japan), using oil-immer­
sion lens (70 Objective lens and numerical aperture 
of 1.4 with Z-series images taken in 1.0 mm slices) 
with NIS Elements Confocal software. A total of eight 
images were acquired randomly from each specimen. 
In biofilm study, four biofilm image features calcu­
lated by COMSTAT [69) were chosen to characterize 
biofilm development by S. aureus and P. aeruginosa on 
PLA thin film composites. These variables, biomass, 
average chickness, roughness coefficient and surface 
to biovolume ratio were selected for interpretation of 
biological and physical characceristics of biofilm [67] 
on these surfaces. Biomass represents the overall vol­
ume of the biofilm, and also provides an estimate of 
the biomass in the biofilm, average thickness provides 
a measure of the spatial size of the biofilm, roughness 
represents a measure of biofilm heterogeneity and sur­
face to biovolume ratio provided us how large a por­
tion of the biofilm is exposed to the nutrients flow. 
Recorded CLSM images were reconstructed using 
IMARIS imaging system (Bitplane AG, Zurich, Swit­
zerland) for biofilm structural quantification in com­
puter statiscics software COMSTAT and presented as 
3D structures. 
The preliminary resulcs obcained from 5 days 
experiments for S. aureus (SHIO00), and Pseudomonas 
aeroginosa on PLA thin film samples are both strains 
ac day 5 had grown into micro colonies, reflecced by 
their low surface to volume ratio compared with bio­
film at day 1. On the other hand, microscopy images 
of S. aureus on the films showed large and high micro­
colonies on PLA, PLAHAp and PLAHApGM samples 
while on PLAGM high single cells and small cell dus­
cers were observed (Figure 6). Confocal images on the 
composites without and wich gentamycin shows the 
intensity of the biofilm formation (Figure 6A & C) and 
the effect of the antibiotics after 24 h (Figure 6B & D). 
le can be suggested that cells were able to attach on 
the surface of PLAGM samples but the drug released 
from the surface suppresses the ability of bacteria to 
make biofilm. Ir could also be envisaged chat there 
is possibility under flow-biofilm-growth conditions 
chat more drugs would be released from the surface 
and may suppress the attachment of bacteria on the 
surfaces. Being high-level antimicrobial resistant in 
Gram-negacive, P. aeroginosa displays similar structure 
characceriscics on the surface of PLA thin films. 
Pseudomonas aeroginosa showed a stronger cendency 
to form microcolonies on the surface of PLA films 
chan S. aureus, which was indicated by higher rough­
ness coefficients. The higher surface to biovolume 
ratio of P. aeroginosa is an indication of its fiat growth 
on the surface compared with S. aureus. This is also 
consistent with the lower average chickness of the 
biofilm it forms on the surface. le was also observed 
chat S. aureus grows faster chan P. aeroginosa on PLA 
surfaces indicated by lower surface to volume ratio, 
higher average thickness and hence higher biomass in 
the biofilm. 
The effect of antibiocic in the films (PLAGM and 
PLAHApGM) against biofilm after 24 h seemed to 
be minimal for S. aureus and no at ail to P. aerogi­
nosa. This is possibly due the fact that starie conditions 
may influence low release rate of drugs from the device 
and also 24 h is not enough cime to realize polymer 
degradation and significant release of antibiotic. 
In summary, ail of the PLA and PLA/HAp genta­
micin loaded chin films under experimental conditions 
exhibiced significant ability to prevent bacterial growth 
even at high concentration of baccerial. The prolonged 
ability to release drug from these films was tested by 
subjecting films for 4 weeks under the same experimen­
tal conditions. Ir was observed that even after releasing 
drugs for 4 weeks, films were still able to release enough 
gentamicin to prevent microbial accivicies. 
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Figure 5. Schematic representation of the drug loading and release method used in this current work. 
GM: Gentamycin; HAp: Hydroxyapatite; PBS: Phosphate-buffered saline; PLA: Polylactic acid. 
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Figure 6. Confocal microscopy images showing 24 h biofilm growth of Staphylococcus aureus. Biofilm growth on (A) PLAHAp, 
(B) PLAHApGM films and their intensity map reflecting biofilm thickness in (C &D), respectively, where (B & D) reflects the
effectiveness of the gentamicin-loaded composites.
GM: Gentamycin; HAp: Hydroxyapatite; PLA: Polylactic acid .
Conclusion & future perspective 
At the moment, we are gradually discovering new ways 
of reproducing structures that are commonly found in 
nature with desirable properties. The use of biological 
microstructures is one versatile approach for the repro­
duction of inorganic structures with identical features. 
This is achieved by using techniques in biomineral­
inspired self-repairing materials chemistry. Multifunc­
tional and multilayered nano coatings and assembly 
will assise us in this endeavor. 
Slow drug delivery and tissue engineering are two 
common tools chat could assise to help us to solve a 
number of bone related deficiencies and repaie. Cur­
rently, the demand is clear for becter tissue engineering 
scaffolds that possess more natural bioresponsive envi­
ronments favorable in guiding the natural processes of 
regeneration. To meet this biological challenge, nove! 
design and synthesis steps must be incorporated into 
the new generation scaffolds. We believe that there 
needs to be a new thinking in tissue scaffold systems 
that are responsive in which the synthesized bioma­
trix evolves in real-time to meet the requirements and 
optimize for the adaptive growth and regeneration 
of human tissues, while delivering the right biogene­
tic materials, pharmaceuticals and minerais. Con­
sequently, the environments of the scaffolds will be 
further adjusted as cells proliferate and differentiate. 
3D printing methods are currently used for a number 
of inorganic and metallic materials and stem cells and 
other biologie structures are incorporated to these new 
generation 3D materials for organ regeneration and 
repa1r. 
During the last decade atomic force microscopy 
was used as a powerful platform in nanomedicine 
for studying and controlling the forces involved in 
ce!! adhesion and biofilm formation. Atomic force 
microscopy is well regarded in measuring the small 
interaction forces between a sharp probe and the sur­
face of a sample. A relatively more recent equipment 
the single-cell force spectroscopy (SCFS), a single 
cell can be attached on the probe in order to mea-
sure the interaction forces between the cell probe and 
a solid substrate or another cells. SCFS-based tech-
niques have recently established as an important tool 
for understanding how microbial pathogens attach to 
surfaces and form biofilms [64]. This can be a turn-
ing point in our fight against biofilms and infections. 
SCFS assays will allow us to clarify the specific and 
nonspecific forces driving cell adhesion on a single-
cell basis. Future work in this area will open new ave-
nues for the development of new tools, devices, meth-
ods and multifunctional coatings capable of detecting 
and destroying biofilms.
Nevertheless, nanosynthesis based on biological 
principles of design and assembly is still in its infancy. 
Better understanding of biofilm formation and the cell 
forces is pertinent. The use of bio-inspired nanofab-
rication techniques including multifunctional multi-
layer coatings in nanoscale thicknesses for slow drug 
delivery and tissue repair is a unique approach. This 
has enormous potential to improve scaffold or lab-on-
chip designs with the capability to diagnose, identify, 
stop biofilm formation, self-repair, micro-evolve and 
osteointegrate fully.
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Executive summary
Background
• Currently, researchers are focusing on the fabrication of new nanocoatings, nanomaterials, nanolaminates
and thin film nanocomposites that are appropriate for applications such as drug delivery and tissue
engineering.
• Innovative approaches driven by nanotechnology are now available for the production of synthetic bone-like
calcium phosphate nanomaterials.
Surface modifications and liposomes for drug delivery applications
• The appropriate circulation time in addition to the dissolution rates within the human body is the main issue
for drug carriers containing nanoparticles.
• The surfaces of nanostructured materials such as nanocoatings can be modified and functionalized with
several types of reagents via various biological, chemical and/or physical methods.
• The surface modification approach can be used to achieve functional improvements by design, better
osteointegration and stability of nanomaterials and nanocoatings in aqueous media.
Infection & osteomyelitis
• Treatment of osteomyelitis can be with immobilization and antibiotic therapy with a number of drugs
including gentamicin.
• Modification or development of thin film or nanocoated multilayer devices with surface properties that have
an effect against microbial adhesion or viability seems to be a promising approach for the prevention of
device-related infections.
• Bacteria adhesion is a complex phenomenon affected by factors such as the properties of surface materials
and characteristics of the bacteria.
Bone repair drug delivery systems & osteomyelitis
• The delivery of antibiotics has become a major focus in research for the use in the treatment of bone
infections or as prevention against infection during surgical interventions.
• Although not fully satisfactory, the implantation of antibiotic-loaded PMMA microspheres and calcium
sulfate based microspheres and powders into the infection site are the approach currently being used in both
orthopedics and in maxillofacial surgery.
• Biodegradable calcium phosphate drug delivery system would be better suited to this endeavor as it can also
introduce calcium and phosphate ions and range of minerals to assist bone growth.
Biodegradable composite thin films
• The use of biodegradable polymer thin films is advantageous in the fight against bacterial infection.
• This is due to their tendency to uptake and release pharmaceuticals and minerals as well as the capability to
degrade over time.
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